Investors

Our Approach

A Commitment to Active and Transparent Shareholder Engagement

At ACELYRIN, we believe that a laser-like focus on creating value for patients is critical to creating value for our shareholders. We are committed to active, accessible and transparent investor relations.
Get in Touch Arrow purple
A Commitment to Active and Transparent Shareholder Engagement
+

Patients dosed with izokibep

+

Dedicated professionals

$ M+

Growth financing committed

Clinical-stage programs

Our Investors

A Blue-chip Biopharma Syndicate

Access
Matrix
Westlake
Surveyor Citadel
Cowen
Decheng
MarshallWace
OrbiMed
RTW
Samsara
Tybourne
VenBio

Latest News & Press Releases

ACELYRIN, INC. Furthers Leadership Position in Immunology with Transformative Acquisition of ValenzaBio
ACELYRIN, INC. to Accelerate Development of Izokibep in Hidradenitis Suppurativa
Former Merck Commercial President Dawn Svoronos joins ACELYRIN, INC. Board of Directors
See All Arrow purple

Upcoming Events

See All Events Arrow purple

Explore Our Site

Meet Our Leadership
Meet Our Leadership
Meet Our Leadership

We are led by experienced biopharma executives with exceptional track records of building strong, innovative and diverse teams across the healthcare industry.

Meet Our Leadership Arrow white
See our pipeline
See Our Pipeline
See Our Pipeline

We are exploring innovative approaches in immunology where we have the opportunity to make a clinically meaningful difference for patients.

See our pipeline Arrow white
Our Science
Our Science
Our Science

We are exploring innovative approaches in immunology where we have the opportunity to make a clinically meaningful difference for patients.

Our Science Arrow white
Our News Center
Our News Center
Our News Center

Access the latest company news and resources.

Our News Center Arrow white